Acesion Pharma launches Phase 2 trial for groundbreaking atrial fibrillation therapy
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
Subscribe To Our Newsletter & Stay Updated